AstraZeneca hit by lung cancer drug setback: Pharma giant halts trials of experimental Volrustomig treatment
Astra said its Volrustomig treatment, when combined with chemotherapy, was unlikely to help lung cancer patients live longer than rival offerings.
AstraZeneca has discontinued a Phase 3 study of one of its cancer drugs. According to Endpoints News, this is the latest in a series of setbacks for the drugmaker.
The study in question was the SAFFRON Phase III trial, which was investigating the combination of Tagrisso (osimertinib) and Orpathys (savolitinib) for patients with EGFR-mutated non-small cell lung cancer.
Investing.com reports that the trial showed statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy. However, despite these results, AstraZeneca decided to end the study.
Brief written by urgent.news from Endpoints News, Investing.com — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
